4.8 Article

Muscular dystrophies

期刊

LANCET
卷 381, 期 9869, 页码 845-860

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(12)61897-2

关键词

-

资金

  1. European Union
  2. UK Medical Research Council
  3. Wellcome Trust
  4. Association Francaise Contre les Myopathies
  5. Muscular Dystrophy Campaign
  6. Great Ormond Street Hospital Biomedical Research Centre
  7. Muscular Dystrophy Association USA
  8. GlaxoSmithKline
  9. Trophos
  10. British Heart Foundation
  11. AVI BioPharma
  12. PTC Therapeutics
  13. Parent Project NL
  14. SMA Europe
  15. Italian Telethon
  16. MRC [MR/K000608/1] Funding Source: UKRI
  17. Medical Research Council [MR/K000608/1] Funding Source: researchfish

向作者/读者索取更多资源

Muscular dystrophies are a heterogeneous group of inherited disorders that share similar clinical features and dystrophic changes on muscle biopsy. An improved understanding of their molecular bases has led to more accurate definitions of the clinical features associated with known subtypes. Knowledge of disease-specific complications, implementation of anticipatory care, and medical advances have changed the standard of care, with an overall improvement in the clinical course, survival, and quality of life of affected people. A better understanding of the mechanisms underlying the molecular pathogenesis of several disorders and the availability of preclinical models are leading to several new experimental approaches, some of which are already in clinical trials. In this Seminar, we provide a comprehensive review that integrates clinical manifestations, molecular pathogenesis, diagnostic strategy, and therapeutic developments.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据